Hikma Finance USA LLC, founded in 2015 and based in New Jersey, serves as a pivotal financing arm for Hikma Pharmaceuticals, a global pharmaceutical company headquartered in the UK. The company primarily focuses on providing financial resources to support Hikma’s extensive portfolio, ensuring liquidity for operations and strategic initiatives.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| HIKLN 3.25% 2025-07-09 USDHikma Finance USA LLC | United States | 2025-07-09 | 3.250 | 0.00 |
| HIKLN 5.13% 2030-07-08 USDHikma Finance USA LLC | United States | 2030-07-08 | 5.125 | 4.90 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Hikma Finance USA LLC has actively participated in the bond market, with its first bond issuance occurring in 2016. Notable issuances include a $300 million bond in 2021, which was well-received and showcased an attractive yield of 4.5%, significantly outperforming industry averages. The 2021 issuance was part of a broader strategy to refinance existing debt and fund expansion initiatives. Currently, its bonds offer features such as call options, providing flexibility amid market conditions, and the company remains in the spotlight due to ongoing efforts to enhance its capital structure.